Fractyl Health Inc. Submits First Clinical Trial Application Module in Europe for RJVA-001 Gene Therapy in Type 2 Diabetes

Reuters

2025/05/19

<a href="https://laohu8.com/S/GUTS">Fractyl Health</a> Inc. Submits First Clinical Trial Application Module in Europe for RJVA-001 Gene Therapy in Type 2 Diabetes

BURLINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS), a company specializing in metabolic therapeutics, has announced the submission of the first module of its Clinical Trial Application $(CTA.UK)$ in Europe for RJVA-001. This gene therapy candidate from Fractyl's Rejuva platform aims to address type 2 diabetes and obesity by expressing glucagon-like peptide-1 (GLP-1) locally in pancreatic beta cells. The therapy is designed to enable physiologic hormone secretion without the high circulating levels associated with current systemic GLP-1 drug therapies, potentially reducing side effects. Pending regulatory clearance, Fractyl plans to begin first-in-human dosing and report preliminary data in 2026. The study will assess the safety, tolerability, and early efficacy of this one-time, pancreas-targeted gene therapy in patients with inadequately controlled type 2 diabetes and obesity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9453194-en) on May 19, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2536683047"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536683047\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536683047?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-19 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536683047","market":"us","top_or_hot":-1,"title":"Fractyl Health Inc. Submits First Clinical Trial Application Module in Europe for RJVA-001 Gene Therapy in Type 2 Diabetes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GUTS\">Fractyl Health</a> Inc. Submits First Clinical Trial Application Module in Europe for RJVA-001 Gene Therapy in Type 2 Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BURLINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS), a company specializing in metabolic therapeutics, has announced the submission of the first module of its Clinical Trial Application <a href=\"https://laohu8.com/S/CTA.UK\">$(CTA.UK)$</a> in Europe for RJVA-001. This gene therapy candidate from Fractyl's Rejuva platform aims to address type 2 diabetes and obesity by expressing glucagon-like peptide-1 (GLP-1) locally in pancreatic beta cells. The therapy is designed to enable physiologic hormone secretion without the high circulating levels associated with current systemic GLP-1 drug therapies, potentially reducing side effects. Pending regulatory clearance, Fractyl plans to begin first-in-human dosing and report preliminary data in 2026. The study will assess the safety, tolerability, and early efficacy of this one-time, pancreas-targeted gene therapy in patients with inadequately controlled type 2 diabetes and obesity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9453194-en) on May 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fractyl Health Inc. Submits First Clinical Trial Application Module in Europe for RJVA-001 Gene Therapy in Type 2 Diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFractyl Health Inc. Submits First Clinical Trial Application Module in Europe for RJVA-001 Gene Therapy in Type 2 Diabetes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-19 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GUTS\">Fractyl Health</a> Inc. Submits First Clinical Trial Application Module in Europe for RJVA-001 Gene Therapy in Type 2 Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BURLINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS), a company specializing in metabolic therapeutics, has announced the submission of the first module of its Clinical Trial Application <a href=\"https://laohu8.com/S/CTA.UK\">$(CTA.UK)$</a> in Europe for RJVA-001. This gene therapy candidate from Fractyl's Rejuva platform aims to address type 2 diabetes and obesity by expressing glucagon-like peptide-1 (GLP-1) locally in pancreatic beta cells. The therapy is designed to enable physiologic hormone secretion without the high circulating levels associated with current systemic GLP-1 drug therapies, potentially reducing side effects. Pending regulatory clearance, Fractyl plans to begin first-in-human dosing and report preliminary data in 2026. The study will assess the safety, tolerability, and early efficacy of this one-time, pancreas-targeted gene therapy in patients with inadequately controlled type 2 diabetes and obesity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9453194-en) on May 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL4q6hJN:1","article_id":"2536683047","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536683047","pubTimestamp":1747652415,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BURLINGTON, Mass., May 19, 2025  -- Fractyl Health, Inc. , a company specializing in metabolic therapeutics, has announced the submission of the first module of its Clinical Trial Application  in Europe for RJVA-001. This gene therapy candidate from Fractyl's Rejuva platform aims to address type 2 diabetes and obesity by expressing glucagon-like peptide-1  locally in pancreatic beta cells. The therapy is designed to enable physiologic hormone secretion without the high circulating levels associated with current systemic GLP-1 drug therapies, potentially reducing side effects. Pending regulatory clearance, Fractyl plans to begin first-in-human dosing and report preliminary data in 2026. The study will assess the safety, tolerability, and early efficacy of this one-time, pancreas-targeted gene therapy in patients with inadequately controlled type 2 diabetes and obesity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT str","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","GUTS":"Fractyl Health","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","BK4082":"医疗保健设备"},"translate_title":"Fractyl Health Inc.在欧洲提交RJVA-001基因疗法治疗2型糖尿病的首个临床试验申请模块","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"GUTS":0.9},"content_text":"Fractyl Health Inc. Submits First Clinical Trial Application Module in Europe for RJVA-001 Gene Therapy in Type 2 Diabetes\n    \n\n        BURLINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS), a company specializing in metabolic therapeutics, has announced the submission of the first module of its Clinical Trial Application $(CTA.UK)$ in Europe for RJVA-001. This gene therapy candidate from Fractyl's Rejuva platform aims to address type 2 diabetes and obesity by expressing glucagon-like peptide-1 (GLP-1) locally in pancreatic beta cells. The therapy is designed to enable physiologic hormone secretion without the high circulating levels associated with current systemic GLP-1 drug therapies, potentially reducing side effects. Pending regulatory clearance, Fractyl plans to begin first-in-human dosing and report preliminary data in 2026. The study will assess the safety, tolerability, and early efficacy of this one-time, pancreas-targeted gene therapy in patients with inadequately controlled type 2 diabetes and obesity.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9453194-en) on May 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}